We provide you with 20 years of free, institutional-grade data for ARGX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ARGX. Explore the full financial landscape of ARGX stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2024-03-08 | 1697862 | ARGX | 6-K | Url |
| 2024-02-29 | 1697862 | ARGX | 6-K | Url |
| 2024-02-20 | 1697862 | ARGX | 6-K | Url |
| 2024-01-18 | 1697862 | ARGX | 6-K | Url |
| 2024-01-08 | 1697862 | ARGX | 6-K | Url |
| 2023-12-20 | 1697862 | ARGX | 6-K | Url |
| 2023-11-28 | 1697862 | ARGX | 6-K | Url |
| 2023-11-17 | 1697862 | ARGX | 6-K | Url |
| 2023-11-01 | 1697862 | ARGX | 6-K | Url |
| 2023-10-31 | 1697862 | ARGX | 6-K | Url |
| 2023-09-21 | 1697862 | ARGX | 6-K | Url |
| 2023-07-27 | 1697862 | ARGX | 6-K | Url |
| 2023-07-21 | 1697862 | ARGX | 6-K | Url |
| 2023-07-17 | 1697862 | ARGX | 6-K | Url |
| 2023-06-30 | 1697862 | ARGX | 6-K | Url |
| 2023-06-21 | 1697862 | ARGX | 6-K | Url |
| 2023-05-05 | 1697862 | ARGX | 6-K | Url |
| 2023-05-05 | 1697862 | ARGX | 6-K | Url |
| 2023-04-18 | 1697862 | ARGX | 6-K | Url |
| 2023-04-17 | 1697862 | ARGX | 6-K | Url |
| 2023-03-16 | 1697862 | ARGX | 20-F | Url |
| 2023-03-16 | 1697862 | ARGX | 6-K | Url |
| 2023-03-02 | 1697862 | ARGX | 6-K | Url |
| 2023-01-30 | 1697862 | ARGX | 6-K | Url |
| 2023-01-27 | 1697862 | ARGX | 6-K | Url |
| 2023-01-09 | 1697862 | ARGX | 6-K | Url |
| 2022-12-12 | 1697862 | ARGX | 6-K | Url |
| 2022-11-30 | 1697862 | ARGX | 6-K | Url |
| 2022-11-22 | 1697862 | ARGX | 6-K | Url |
| 2022-10-27 | 1697862 | ARGX | 6-K | Url |
| 2022-09-21 | 1697862 | ARGX | 6-K | Url |
| 2022-09-08 | 1697862 | ARGX | 6-K | Url |
| 2022-08-12 | 1697862 | ARGX | 6-K | Url |
| 2022-07-28 | 1697862 | ARGX | 6-K | Url |
| 2022-06-27 | 1697862 | ARGX | 6-K | Url |
| 2022-05-19 | 1697862 | ARGX | 6-K | Url |
| 2022-05-05 | 1697862 | ARGX | 6-K | Url |
| 2022-03-25 | 1697862 | ARGX | 6-K | Url |
| 2022-03-22 | 1697862 | ARGX | 6-K | Url |
| 2022-03-21 | 1697862 | ARGX | 20-F | Url |
| 2022-03-03 | 1697862 | ARGX | 6-K | Url |
| 2022-01-20 | 1697862 | ARGX | 6-K | Url |
| 2022-01-10 | 1697862 | ARGX | 6-K | Url |
| 2022-01-07 | 1697862 | ARGX | 6-K | Url |
| 2021-12-22 | 1697862 | ARGX | 6-K | Url |
| 2021-07-29 | 1697862 | ARGX | 6-K | Url |
| 2021-06-07 | 1697862 | ARGX | 6-K | Url |
| 2021-06-01 | 1697862 | ARGX | 6-K | Url |
| 2021-05-14 | 1697862 | ARGX | 6-K | Url |
| 2021-05-11 | 1697862 | ARGX | 6-K | Url |
| 2021-03-30 | 1697862 | ARGX | 20-F | Url |
| 2021-03-30 | 1697862 | ARGX | 6-K | Url |
| 2021-02-04 | 1697862 | ARGX | 6-K | Url |
| 2021-02-01 | 1697862 | ARGX | 6-K | Url |
| 2021-01-08 | 1697862 | ARGX | 6-K | Url |
| 2021-01-06 | 1697862 | ARGX | 6-K | Url |
| 2020-11-23 | 1697862 | ARGX | 6-K | Url |
| 2020-10-22 | 1697862 | ARGX | 6-K | Url |
| 2020-10-06 | 1697862 | ARGX | 6-K | Url |
| 2020-07-31 | 1697862 | ARGX | 6-K | Url |
| 2020-07-30 | 1697862 | ARGX | 6-K | Url |
| 2020-05-29 | 1697862 | ARGX | 6-K | Url |
| 2020-05-26 | 1697862 | ARGX | 6-K | Url |
| 2020-05-14 | 1697862 | ARGX | 6-K | Url |
| 2020-05-12 | 1697862 | ARGX | 6-K | Url |
| 2020-03-31 | 1697862 | ARGX | 20-F | Url |
| 2020-03-31 | 1697862 | ARGX | 6-K | Url |
| 2020-02-27 | 1697862 | ARGX | 6-K | Url |
| 2020-01-13 | 1697862 | ARGX | 6-K | Url |
| 2020-01-09 | 1697862 | ARGX | 6-K | Url |
| 2019-12-09 | 1697862 | ARGX | 6-K | Url |
| 2019-11-08 | 1697862 | ARGX | 6-K | Url |
| 2019-11-06 | 1697862 | ARGX | 6-K | Url |
| 2019-10-24 | 1697862 | ARGX | 6-K | Url |
| 2019-10-15 | 1697862 | ARGX | 6-K | Url |
| 2019-08-01 | 1697862 | ARGX | 6-K | Url |
| 2019-05-28 | 1697862 | ARGX | 6-K | Url |
| 2019-05-22 | 1697862 | ARGX | 6-K | Url |
| 2019-05-09 | 1697862 | ARGX | 6-K | Url |
| 2019-05-08 | 1697862 | ARGX | 6-K | Url |
| 2019-03-26 | 1697862 | ARGX | 20-F | Url |
| 2019-03-26 | 1697862 | ARGX | 6-K | Url |
| 2019-03-14 | 1697862 | ARGX | 6-K | Url |
| 2019-02-28 | 1697862 | ARGX | 6-K | Url |
| 2019-02-04 | 1697862 | ARGX | 6-K | Url |
| 2019-01-18 | 1697862 | ARGX | 6-K | Url |
| 2018-12-03 | 1697862 | ARGX | 6-K | Url |
| 2018-12-03 | 1697862 | ARGX | 6-K | Url |
| 2018-11-01 | 1697862 | ARGX | 6-K | Url |
| 2018-10-25 | 1697862 | ARGX | 6-K | Url |
| 2018-10-09 | 1697862 | ARGX | 6-K | Url |
| 2018-09-20 | 1697862 | ARGX | 6-K | Url |
| 2018-09-17 | 1697862 | ARGX | 6-K | Url |
| 2018-09-06 | 1697862 | ARGX | 6-K | Url |
| 2018-08-29 | 1697862 | ARGX | 6-K | Url |
| 2018-08-22 | 1697862 | ARGX | 6-K | Url |
| 2018-08-02 | 1697862 | ARGX | 6-K | Url |
| 2018-07-24 | 1697862 | ARGX | 6-K | Url |
| 2018-07-17 | 1697862 | ARGX | 6-K | Url |
| 2018-06-28 | 1697862 | ARGX | 6-K | Url |
| 2018-06-20 | 1697862 | ARGX | 6-K | Url |
| 2018-06-14 | 1697862 | ARGX | 6-K | Url |
| 2018-06-07 | 1697862 | ARGX | 6-K | Url |
| 2018-05-09 | 1697862 | ARGX | 6-K | Url |
| 2018-04-24 | 1697862 | ARGX | 6-K | Url |
| 2018-04-12 | 1697862 | ARGX | 6-K | Url |
| 2018-04-09 | 1697862 | ARGX | 6-K | Url |
| 2018-03-26 | 1697862 | ARGX | 20-F | Url |
| 2018-03-26 | 1697862 | ARGX | 6-K | Url |
| 2018-03-22 | 1697862 | ARGX | 6-K | Url |
| 2018-03-16 | 1697862 | ARGX | 6-K | Url |
| 2018-03-01 | 1697862 | ARGX | 6-K | Url |
| 2017-12-11 | 1697862 | ARGX | 6-K | Url |
| 2017-11-07 | 1697862 | ARGX | 6-K | Url |
| 2017-10-30 | 1697862 | ARGX | 6-K | Url |
| 2017-10-26 | 1697862 | ARGX | 6-K | Url |
| 2017-09-26 | 1697862 | ARGX | 6-K | Url |
| 2017-09-25 | 1697862 | ARGX | 6-K | Url |
| 2017-09-22 | 1697862 | ARGX | 6-K | Url |
| 2017-09-20 | 1697862 | ARGX | 6-K | Url |
| 2017-08-24 | 1697862 | ARGX | 6-K | Url |
| 2017-08-23 | 1697862 | ARGX | 6-K | Url |
| 2017-07-07 | 1697862 | ARGX | 6-K | Url |
| 2017-06-20 | 1697862 | ARGX | 6-K | Url |
| 2017-06-14 | 1697862 | ARGX | 6-K | Url |
| 2017-05-23 | 1697862 | ARGX | 6-K | Url |
argenx SE(NASDAQ:ARGX)Â 
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia...
Website: http://www.argenx.com
Founded: 2008
Full Time Employees: 186
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ARGX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.